医学
Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
Informing the debate: hypomethylating agents/venetoclax or intensive chemotherapy to treat acute myeloid leukemias
作者Michael Daunov; Yogen Saunthararajah
作者单位1. Department of Hematology and Oncology, University Hospitals; 2. School of Medicine, Case Western Reserve University; 3. Taussig Cancer Institute, Cleveland Clinic
The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review
作者Maïfa Belghoul; Andrea Kuhnl; Timothy Chevassut; Robin Sanderson; George Mikhaeel; Reuben Benjamin; Piers Patton; John Jones
作者单位1. Department of Clinical Experimental Medicine, Brighton and Sussex Medical School; 2. University Hospitals Sussex NHS Trust; 3. King’s College Hospital
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
作者Joshua Richter; Hans C. Lee; Sundar Jagannath; Jeffrey A. Zonder; James E. Hoffman; Zheng-Yi Zhou; Viviana Garcia-Horton; Mirko Fillbrunn; Hongjue Wang; Matthew Mattera; Timothy J. Inocencio; Yingxin Xu; James Harnett; Tito Roccia; Glenn S. Kroog; Karen Rodriguez Lorenc; Kate Knorr; Qiufei Ma; Naresh Bumma
作者单位1. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; 2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 3. Karmanos Cancer Institute, Wayne State University School of Medicine; 4. University of Miami Health System; 5. Analysis Group, Inc.; 6. Regeneron Pharmaceuticals, Inc.; 7. The Ohio State University Comprehensive Cancer Center
CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial
作者Priyanka Mehta; Roderick Murphy; Saemi Park; Stefan Faderl; Tomas Skacel; Abin Thomas; Sean Johnson; Alex Legg
作者单位1. University Hospitals Bristol and Weston NHS Foundation Trust; 2. Jazz Pharmaceuticals plc; 3. Centre for Trials Research, Cardiff University
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
作者Oren Pasvolsky; Curtis Marcoux; Denái R. Milton; Mark R. Tanner; Qaiser Bashir; Samer Srour; Neeraj Saini; Paul Lin; Jeremy Ramdial; Yago Nieto; Guilin Tang; Yosra Aljawai; Asad A. Haider; Bilal Islam; Hans C. Lee; Krina K. Patel; Mahmoud R. Gaballa; Partow Kebriaei; Sheeba K. Thomas; Robert Z. Orlowski; Richard E. Champlin; Elizabeth J. Shpall; Muzaffar H. Qazilbash
作者单位1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center; 2. Division of Hematology, Dalhousie University; 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center; 4. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center; 5. Department of Hematopathology, The University of Texas MD Anderson Cancer Center; 6. Department of Medicine, Dow University of Health Sciences; 7. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study
作者Annasofia Holopainen; Hanna-Riikka Lehto; Taru Kuittinen; Mikko Nuutinen; Kristiina Tyynelä-Korhonen; Annamarja Lamminmäki; Tiina Saarto; Timo Carpén
作者单位1. Department of Hematology, Kuopio University Hospital, The Wellbeing Services County of North Savo; 2. Faculty of Health Sciences, Institute of Clinical Medicine, University of Eastern Finland; 3. Department of General Medicine, Division of Palliative Medicine, University of Turku; 4. Palliative Care Centre and Hospital at Home, The Wellbeing Services County of Western Uusimaa; 5. Nordic Healthcare Group; 6. Palliative Care Center, Päijät-Häme Wellbeing Services County; 7. Cancer Center, Kuopio University Hospital, The Wellbeing Services County of North Savo; 8. Palliative Care Center, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。